Virtus ETF Advisers LLC Reduces Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX)

Virtus ETF Advisers LLC cut its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX) by 48.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 852 shares of the company’s stock after selling 799 shares during the period. Virtus ETF Advisers LLC’s holdings in Arcellx were worth $65,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ACLX. Lord Abbett & CO. LLC grew its position in shares of Arcellx by 2.1% during the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company’s stock worth $74,478,000 after acquiring an additional 18,004 shares during the last quarter. Avanza Fonder AB purchased a new position in shares of Arcellx during the fourth quarter worth approximately $184,000. KBC Group NV grew its position in shares of Arcellx by 37.3% during the fourth quarter. KBC Group NV now owns 1,388 shares of the company’s stock worth $106,000 after acquiring an additional 377 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Arcellx by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,466 shares of the company’s stock worth $879,000 after acquiring an additional 1,127 shares during the last quarter. Finally, Legato Capital Management LLC grew its position in shares of Arcellx by 36.1% during the fourth quarter. Legato Capital Management LLC now owns 5,999 shares of the company’s stock worth $460,000 after acquiring an additional 1,591 shares during the last quarter. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Arcellx news, insider Christopher Heery sold 10,155 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $63.79, for a total value of $647,787.45. Following the completion of the sale, the insider now owns 37,486 shares of the company’s stock, valued at approximately $2,391,231.94. This trade represents a 21.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kavita Patel sold 1,500 shares of the firm’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $63.16, for a total value of $94,740.00. The disclosure for this sale can be found here. Insiders sold a total of 54,455 shares of company stock valued at $3,408,458 over the last three months. 6.24% of the stock is currently owned by company insiders.

Arcellx Price Performance

Shares of NASDAQ ACLX opened at $64.55 on Tuesday. The stock has a fifty day moving average price of $64.76 and a 200 day moving average price of $74.65. Arcellx, Inc. has a 1-year low of $47.88 and a 1-year high of $107.37. The company has a market cap of $3.55 billion, a PE ratio of -90.91 and a beta of 0.33.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The company had revenue of $15.27 million for the quarter, compared to analyst estimates of $27.42 million. Analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).